Prim-O-glucosylcimifugin suppresses M2 macrophage polarization via the JAK2-STAT6-PPARγ pathway to alleviate allergic asthma
Year: 2026
Type: preprint
Abstract: Background Allergic asthma (AA) is a chronic respiratory disease closely linked to immune-inflammatory responses driven by M2 macrophage polarization. PrimO-glucosylcimifugin (POG), a natural bioactive compound from Saposhnikovia divaricata (SD), alleviates inflammation in acute lung injury mice, but whether it mitigates AA by modulating M2 macrophage polarization remains unclear. Objective This study investigated POG’s effects on AA and its mechanisms in regulating M2 macrophage polarization. Methods LC-MS profiled the SD/Prunus mume (PM) combination, and network pharmacology predicted its main active components and key anti-AA mechanisms. Ovalbumin (OVA) plus IL-4 established AA models in mice and RAW264.7 cells. Lung protection was assessed by histopathology, lung indices, and type II immune inflammatory cytokine markers. Flow Cytometry, RT-qPCR, immunofluorescence, and Western blot examined key genes/proteins in the JAK2-STAT6-PPARγ axis. Results LC-MS-based network pharmacology identified POG as the key SD/PM active ingredient alleviating AA. Pharmacodynamic evaluation showed POG effectively alleviated OVA-induced airway inflammation and pulmonary histopathological damage in AA mice. Mechanistically, POG inhibited M2 macrophage polarization by downregulating key JAK2-STAT6-PPARγ axis factors. Conclusion POG ameliorates AA by reducing type II immune factor release through JAK2-STAT6-PPARγ-mediated inhibition of M2 macrophage polarization. This study clarifies POG’s anti-AA mechanism and supports its clinical development.
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
Award: G5459649692
OpenAlex ID: W7235138726
